Drug results: 2
fulvestrant | An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer. | |
elacestrant | Elacestrant is an estrogen receptor antagonist that binds to estrogen receptor-alpha (ERalfa). In ER-positive (ER+) HER2-negative (HER2-) breast cancer cells, elacestrant inhibited 17beta-estradiol mediated cell proliferation at concentrations inducing degradation of ERalfa protein mediated through proteasomal pathway. Elacestrant demonstrated in vitro and in vivo antitumor activity including in ER+ HER2- breast cancer models resistant to fulvestrant and cyclin-dependent kinase 4/6 inhibitors and those harboring estrogen receptor 1 gene (ESR1) mutations. |
Citing DrugCentral © 2024. License